WHAT IS CLAIMED IS:

1. An ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression, the ophthalmic lens comprising:

a contact lens formed from a first material and incorporating myopia control optics; and

an antimuscarinic agent incorporated into a mixture being at least one of affixed to or incorporated into the first material forming the contact lens, the antimuscarinc agent being configured to elute into the eye over a predetermined period of time.

2. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, wherein the first material comprises a hydrogel.

3. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, wherein the first material comprises a silicon hydrogel.

4. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, wherein the antimuscarinic agent comprises atropine.

5. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, wherein the antimuscarinic agent comprises atropine sulphate.

6. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, wherein the antimuscarinic agent comprises pirenzepine.

7. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 4, wherein the antimuscarinic agent mixture comprises atropine dissolved in buffered saline solution.

8. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 5, wherein the antimuscarinic agent mixture comprises atropine sulphate dissolved in buffered saline solution.

9. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 6, wherein the antimuscarinic agent mixture comprises pirenzepine dissolved in buffered saline solution.

10. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, further comprises a photochromic agent incorporated into the contact lens.

11. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, further comprises a neutral filter dye incorporated into the contact lens.

12. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, wherein the contact lens comprises a daily wear lens.

13. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, wherein the contact lens comprises a reusable lens.

14. An ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression, the ophthalmic lens comprising:

a contact lens formed from a first material and incorporating myopia control optics; and

a dopamine agonists incorporated into a mixture being at least one of affixed to or incorporated into the first material forming the contact lens, the

dopamine agonist being configured to elute into the eye over a predetermined period of time.

CLAIMS:

1. An ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression, the ophthalmic lens comprising:

a contact lens formed from a first material and incorporating myopia control optics; and

an anti-muscarinic agent incorporated into a mixture being at least one of affixed to or incorporated into the first material forming the contact lens, the anti-muscarinic agent being configured to elute into the eye over a predetermined period of time wherein the anti-muscarinic agent mixture includes:

a) atropine; or

b) atropine sulphate; or

c) pirenzepine;

dissolved in a buffered saline solution.

2. The ophthalmic lens for at least one of inhibiting, preventing and/or controlling myopia progression according to Claim 1, wherein the contact lens comprises a daily wear lens and/or a reusable lens.